Novo outlines diversification strategy with new pipeline assets and bolt-on deals

Novo Pharmaceuticals' chief executive Maziar Mike Doustdar used the company's recent capital-markets day in London to lay out a diversification plan. He said the rebranded firm will focus on expanding its pipeline with additional assets and pursuing bolt-on acquisitions.

The announcement follows Novo's rebrand that was unveiled the week before, signaling a broader shift in corporate identity and direction. Doustdar emphasized that the new strategy aims to reduce reliance on any single product line and to strengthen the company's long-term growth prospects.

While no specific deals or drug candidates were detailed, the CEO indicated that the company is actively evaluating opportunities that align with the diversification goals. Investors and industry observers will be watching for follow-up announcements as Novo seeks to execute the plan.

The presentation was part of a broader investor-focused event, suggesting that Novo is seeking to communicate its future roadmap to the market and to attract capital for the upcoming initiatives.